The conditions that produced a sluggish biopharma M&A environment in 2018 persist, with bolt-on deals like Lilly/Loxo more likely than another mega-merger.
Bristol-Myers Squibb Co.’s $74bn acquisition of Celgene Corp. doesn’t necessarily portend a hectic year of biopharmaceutical M&A, according to EY Global Life Sciences Transaction Leader Peter Behner, nor does Eli Lilly & Co.’s $8bn purchase of Loxo Oncology Inc. – but weighing transformational M&A versus bolt-on deals, he predicts more of the latter.
Interviewed during the J.P. Morgan Healthcare Conference Jan. 8, where EY released its 2019 M&A Firepower Report estimating the M&A...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
